SanegeneBio Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $110M

  • Investors
  • 25

SanegeneBio General Information

Description

Developer of RNA interference therapeutics designed to treat diseases with significant unmet medical needs. The company offers therapeutics based on proprietary N-acetylgalactosamine and extrahepatic delivery platforms, enabling healthcare providers to address autoimmune, cardiovascular, metabolic, obesity and coagulation-related diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 301, Building 2, Area B
  • Phase III Project
  • Suzhou, Jiangsu 215000
  • China
+86 0512
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Room 301, Building 2, Area B
  • Phase III Project
  • Suzhou, Jiangsu 215000
  • China
+86 0512

SanegeneBio Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SanegeneBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series B) 20-Nov-2025 $110M Completed Clinical Trials - Phase 2
4. Early Stage VC (Series A1) 30-Sep-2024 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 01-Sep-2021 Completed Pre-Clinical Trials
2. Seed Round 07-Feb-2021 $12M $12M Completed Startup
1. Accelerator/Incubator Completed Startup
To view SanegeneBio’s complete valuation and funding history, request access »

SanegeneBio Patents

SanegeneBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260357263-A1 Small interfering rna targeting lp(a) and uses thereof Pending 29-Nov-2023
US-20240309383-A1 Small interfering rna targeting hbv and uses thereof Pending 24-Feb-2023
WO-2024175111-A2 Small interfering rna targeting hbv and uses thereof Inactive 24-Feb-2023
WO-2024175111-A3 Small interfering rna targeting hbv and uses thereof Inactive 24-Feb-2023 C12N15/1131

SanegeneBio Investors (25)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hillhouse Capital PE/Buyout Minority
Invus (Private Equity) PE/Buyout Minority
Lake Bleu Capital Hedge Fund Minority
Legend Capital Venture Capital Minority
Lilly USA Corporation Minority
You’re viewing 5 of 25 investors. Get the full list »

SanegeneBio FAQs

  • When was SanegeneBio founded?

    SanegeneBio was founded in 2021.

  • Where is SanegeneBio headquartered?

    SanegeneBio is headquartered in Suzhou, China.

  • What industry is SanegeneBio in?

    SanegeneBio’s primary industry is Drug Discovery.

  • Is SanegeneBio a private or public company?

    SanegeneBio is a Private company.

  • What is SanegeneBio’s current revenue?

    The current revenue for SanegeneBio is .

  • How much funding has SanegeneBio raised over time?

    SanegeneBio has raised $247M.

  • Who are SanegeneBio’s investors?

    Hillhouse Capital, Invus (Private Equity), Lake Bleu Capital, Legend Capital, and Lilly USA are 5 of 25 investors who have invested in SanegeneBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process